Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart shield? diabetes drug tested to prevent chemo heart damage

NCT ID NCT07245069

Recruiting now Prevention Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether dapagliflozin, a drug used for diabetes and heart failure, can prevent heart damage caused by a common type of chemotherapy (anthracyclines) in breast cancer patients. One hundred women will receive either dapagliflozin or a placebo daily during their chemotherapy. Researchers will monitor heart function and blood markers to see if the drug offers protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dapagliflozin
What this could lead to
If it works, this could point toward a way to protect the heart during breast cancer chemotherapy, reducing the risk of long-term heart problems.
What could go wrong
This is a small, early-stage (Phase 2) study, so results may not be definitive. Dapagliflozin may not prevent heart damage, and it can have side effects like dehydration or urinary infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm heart failure Inflammation cardiomyopathy due to anthracyclines prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTHRACYCLINE-INDUCED CARDIAC TOXICITY ARTERIAL STIFFNESS BREAST CANCER ENDOTHELIAL FUNCTION (FMD) HEART FAILURE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Centre Ljubljana

    RECRUITING

    Ljubljana, 1000, Slovenia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.